Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.7M | -$22.5M | -$39.7M | -$63.1M | -$36.4M | -$56.2M | -$62.7M | -$42.8M | -$60.1M | -$35.3M |
| Net income | -$18.7M | -$22.3M | -$38.9M | -$60.8M | -$37.6M | -$57.8M | -$62.0M | -$37.5M | -$55.9M | -$33.8M |
| EPS (diluted) | -$1.65 | -$1.40 | -$1.79 | -$2.24 | -$1.11 | -$1.07 | -$1.06 | -$0.64 | -$0.94 | -$0.56 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.1M | -$19.2M | -$29.9M | -$45.0M | -$37.5M | -$42.6M | -$56.6M | -$30.3M | -$43.2M | -$33.3M |
| Capital expenditures | $11.8K | $24.8K | $263K | $9.53K | — | $7.81K | $16.3K | $0.00 | — | — |
| Free cash flow | -$15.2M | -$19.2M | -$30.1M | -$45.0M | — | -$42.6M | -$56.7M | -$30.3M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.0M | $20.0M | $47.4M | $44.4M | $77.9M | $230M | $144M | $143M | $54.5M | $70.0M |
| Total assets | $25.2M | $44.2M | $95.1M | $75.5M | $83.4M | $233M | $181M | $148M | $105M | $72.1M |
| Total liabilities | $3.54M | $4.57M | $8.47M | $27.4M | $23.8M | $27.4M | $30.3M | $28.5M | $33.6M | $27.8M |
| Long-term debt | $1.24M | $1.22M | — | $14.5M | $11.4M | $15.5M | $14.9M | $0.00 | $15.0M | $0.00 |
| Shareholders' equity | $21.6M | $39.6M | $86.6M | $48.1M | $59.5M | $206M | $151M | $120M | $71.0M | $44.3M |
| Retained earnings | -$77.3M | -$99.6M | -$139M | -$199M | -$237M | -$295M | -$357M | -$394M | -$450M | -$484M |
| Shares (wtd avg diluted) | 12.6M | 19.1M | 26.2M | 28.7M | 38.7M | 54.0M | 58.4M | 58.9M | 59.5M | 60.1M |
Every figure is extracted from Aldeyra Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.